title: Clinical study of Trilogy Detoxicating Therapy combined with routine Western medicine on patients with chronic renal failure.
abstract: OBJECTIVE
  To investigate the mechanism of Trilogy Detoxicating Therapy in treating patients with chronic renal failure (CRF).
  
  
  METHODS
  A total of 142 patients were assigned to the Trilogy Detoxicating Therapy group (the treatment group, 82 patients) and the Western medicine treatment group (the control group, 60 patients). All of the patients were treated with NovoNorm 1 mg and metformin hydrochloride tablets 0.15 g thrice per day for lowering the blood glucose, as well as Perindopril 4 mg twice daily for lowering blood pressure, recombinant human erythropoietin 2 000 U and a hypodermic injection thrice a week for rectifying anemia, 30 days as one course of treatment, and all patients were treated for two courses. Patients in the treatment group were treated with the Trilogy Detoxicating Therapy [dispersing the five-zang organs, expelling toxins through colonic dialysis and skin dialysis fumigation] in addition to the aforementioned drugs. Parameters observed and recorded in the study included renal function [serum creatinine (SCr), blood urea nitrogen (BUN)], blood lipids [triglyceride (TG), total cholesterol (TC), low-density lipoprotein C (LDL-C), high-density lipoprotein C (HDL-C)], plasma total protein (TP), hemoglobin (Hb), serum interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) before and after the treatment.
  
  
  RESULTS
  After two courses of treatment, the levels of SCr, BUN, TG, TC, LDL-C, serum IL-6 and TNF-alpha decreased significantly, meanwhile HDL-C increased in the treatment group (P<0.05 or P<0.01). In contrast, no obvious changes of the above mentioned items occurred in the control group. In both groups, the levels of TP and Hb were significantly elevated (P<0.05 or P<0.01), but the changes were more obvious in the treatment group (P<0.01).
  
  
  CONCLUSIONS
  Trilogy Detoxicating Therapy played a therapeutic role on patients with CRF possibly through lowering the levels of blood lipids, serum IL-6 and TNF-alpha.
authors.affiliation: Department of the Integrated Chinese and Western Medicine, Shaanxi Province Traditional Chinese Medical Key Department of Nephrology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, China. wuxili1984@163.com
authors.forename: Xi-li
authors.initials: XL
authors.lastname: Wu
authors.forename: Wan-sen
authors.initials: WS
authors.lastname: Sun
authors.forename: Wang-gang
authors.initials: WG
authors.lastname: Zhang
authors.forename: Cheng-lin
authors.initials: CL
authors.lastname: Qiao
authors.forename: Run-xia
authors.initials: RX
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000032:analysis; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D008516:Medicine, Chinese Traditional / Q000009:adverse effects; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D001798:Blood Proteins; D006454:Hemoglobins; D015850:Interleukin-6; D008055:Lipids; D014409:Tumor Necrosis Factor-alpha; D003404:Creatinine